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Abstract
Background: Case descriptions suggest IBS patients are more likely to have other disorders,
including migraine, fibromyalgia, and depression. We sought to examine the prevalence of these
conditions in cohorts of people with and without IBS.
Methods: The source of data was a large U.S. health plan from January 1, 1996 though June 30,
2002. We identified all people with a medical claim associated with an ICD-9 code for IBS. A non-
IBS cohort was a random sample of people with an ICD-9 code for routine medical care. In the
cohorts, we identified all claims for migraine, depression, and fibromyalgia. We estimated the
prevalence odds ratios (PORs) of each of the three conditions using the Mantel-Haenszel method.
We conducted quantitative sensitivity analyses to quantify the impact of residual confounding and
in differential outcome identification.
Results: We identified 97,593 people in the IBS cohort, and a random sample of 27,402 people to
compose the non-IBS comparison cohort. With adjustment, there was a 60% higher odds in the
IBS cohort of having any one of the three disorders relative to the comparison cohort (POR 1.6,
95% CI 1.5 – 1.7). There was a 40% higher odds of depression in the IBS cohort (POR 1.4, 95% CI
1.3 – 1.4). The PORs for fibromyalgia and migraine were similar (POR for fibromyalgia 1.8, 95% CI
1.7 – 1.9; POR for migraine 1.6, 95% CI 1.4 – 1.7). Differential prevalence of an unmeasured
confounder, or imperfect sensitivity or specificity of outcome detection would have impacted the
observed results.
Conclusion: People in the IBS cohort had a 40% to 80% higher prevalence odds of migraine,
fibromyalgia, and depression.
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Background
Irritable bowel syndrome (IBS) is a functional disorder of
the gastrointestinal tract, which results in the clinical
symptoms of altered bowel habits and abdominal pain
[1,2]. It is characterized by three specific forms: diarrhea-
predominant, constipation-predominant, and alternating
between diarrhea and constipation. While there is no
diagnostic instrument to screen and diagnose people with
the condition, the Rome II criteria are the established
method of diagnosis for inclusion in clinical trials and by
some clinicians [3].
People with IBS are reportedly more likely to have other
disorders including migraine, fibromyalgia, and depres-
sion. These disorders are known in some literature as
"affective spectrum disorders", or "functional somatic
syndromes" [4,5]. This hypothesis, first proposed about
fifteen years ago [4], was developed on the basis of obser-
vations that people treated with antidepressant therapy
for these conditions responded favorably, since tricyclic
antidepressants affect pain thresholds. Such findings pro-
moted speculation that these disorders may actually be
manifestations of the same underlying biologic mecha-
nism. In an early study of this hypothesis that focused on
people with fibromyalgia, 39% were found to have symp-
toms consistent with IBS, 45% had migraine, and 42%
had chronic fatigue syndrome [6]. A more recent study
showed a familial association among patients with major
depressive disorder and fibromyalgia, IBS, and migraine
[7]. Another study based on data from a Canadian clinic
used latent class models to categorize reported symptoms
from a survey, and suggested that a single diagnostic entity
could replace the separate diagnostic criteria used to
define fibromyalgia, IBS, depression and chronic fatigue
syndrome [8]. Others have noted that the case definitions
for each condition share similar diagnostic elements, and
that perhaps IBS could be alternatively diagnosed as fibro-
myalgia or migraine, if a person had sought medical care
from a rheumatologist or neurologist instead of a gastro-
enterologist [5]. Hypotheses surrounding fibromyalgia
have been reinforced in data from a cross-sectional study
in 1999 showing 32% of patients with IBS having symp-
toms of fibromyalgia, compared with 4% of patients with-
out IBS [9]. Results from a more recent study showed
fibromyalgia occurring in 20% of patients with IBS [10].
Data on the prevalence of depression in conjunction with
IBS has been less clear. One study showed no association
with psychological factors and health seeking behavior
among IBS patients [11]. In contrast, a review of previ-
ously published work showed comorbidity of depression,
anxiety, and somatoform disorders occurring in up to
94% of people with IBS [12].
Although the hypothesis surrounding the prevalence of
these three disorders in association with IBS has been pre-
viously explored, many published studies have been
based on data from clusters of case reports or from small
clinical practices. Further limitations in these studies have
been the lack of a reference cohort, and inability to fully
control for potentially confounding variables. To address
the validity concerns in previous research, we sought to
examine the prevalence of other disorders, specifically
migraine, fibromyalgia, and depression in cohorts of peo-
ple with IBS and without IBS.
Methods
Data source
The context for this research was data from a large,
national health insurance plan in the U.S. Coverage
through the plan is available as an employment benefit
and its members either are employed or are spouses and
dependents of the employed subscriber. A research data-
base contains automated insurance claims for medical
services, including those provided by a physician or hos-
pital, along with claims for prescriptions filled at an out-
patient pharmacy. For this research, we used data from
eight geographically diverse states with the largest concen-
tration of health plan membership, primarily in the Mid-
west and south/southeastern United States.
Study population
We identified all people with at least one medical claim
associated with a diagnosis of irritable bowel syndrome
between January 1, 1996 and June 30, 2002. The ICD-9
CM code corresponding to a diagnosis of irritable bowel
syndrome is 564.1 [13]. To identify a group of people to
serve as a comparison cohort, we identified a five percent
simple random sample of all health plan enrollees that
sought routine medical care with a physician and did not
have an IBS diagnosis while enrolled with the health plan
during the same period. The ICD-9-CM diagnosis code
corresponding to a diagnosis of routine medical care is
V70.0 [13]. We created datasets of all medical claims for
people in the IBS and comparison cohorts, including
those related to physician and hospital services, along
with all outpatient pharmacy dispensing claims, and all
dates of health plan enrollment.
Identification of migraine, depression, and fibromyalgia
Among people in each of the two cohorts, we identified all
medical and prescription claims relating to the occurrence
of medical care for migraine, depression, and fibromyal-
gia. To decrease the probability of including claims for
diagnostic testing, where the ICD-9 code may not reflect a
definitive diagnosis (i.e. a "rule-out" diagnosis), we devel-
oped operational definitions for each of the three condi-
tions. The operational definitions were as follows:
Medical care for migraine was defined as claims for a phy-BMC Gastroenterology 2006, 6:26 http://www.biomedcentral.com/1471-230X/6/26
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sician visit or hospitalization associated with a diagnosis
for migraine, and outpatient prescription claims associ-
ated with dispensing of an anti-migraine drug (ergot alka-
loid or triptan). To be classified as having migraine,
people were required to fulfill both the diagnosis and the
prescription criteria. Medical care for depression was
defined as claims for visits with a mental health provider
associated with a diagnosis for depression. We defined
medical care for fibromyalgia as claims for a physician
visit or hospitalization associated with a diagnosis of
fibromyalgia.
Data analysis
To accommodate the nature of the dynamic populations
in this study, and that migraine, fibromyalgia, and depres-
sion are chronic diseases without clear dates of onset, in
these data we calculated the prevalence of each of the con-
ditions in the following manner. For each month of the
study period, we created a series of three dichotomous
variables indicating whether the person received medical
care for migraine, depression, or fibromyalgia, according
to the operational definitions previously described. A per-
son who fulfilled the operational definition for one of
these conditions had the indicator variable for that varia-
ble flagged as one in that specific month. Once an individ-
ual fulfilled the operational definition in one of the
months, all subsequent monthly indicator variables for
that condition were flagged as one. The prevalence of each
condition in the IBS and non-IBS cohorts was calculated
as the fraction of people flagged with the condition as of
the last month of the study period. Thus, for the purpose
of estimating disease prevalence, a person with a short-
lived depressive episode would be given the same weight
as a person with depression lasting several years. To exam-
ine whether clustering any of the three conditions
occurred in people, as has been suggested among people
with IBS, we also calculated the prevalence of having two
conditions and the prevalence of having all three condi-
tions. For a measure of association, we used the preva-
lence odds ratio (POR). The crude prevalence odds ratio
for each condition was calculated as the prevalence odds
among the IBS cohort divided by the prevalence odds
among the non-IBS cohort.
Assessment of bias
Information bias stemming from the use of medical
claims to identify each of the three conditions was a
potential problem. People in the IBS cohort may be
greater consumers of health care, and due to increased
contact with health care providers, they could have a
greater opportunity for a diagnosis of other diseases,
including these three disorders. To address this source of
possible bias, we created a variable representing the mean
cost of all medical and pharmacy services reimbursed by
the health plan during the study period per person-month
of health plan enrollment, and treated it like a confound-
ing variable in the analysis. Cost of medical and pharmacy
services has been used in previous studies using these data
as a proxy measure for disease severity [14,15]. Excluded
from this cost measure was the cost of prescriptions and
diagnoses associated with migraine, depression, and
fibromyalgia. We stratified people according to quintiles
of the distribution of mean monthly total medical cost.
We also considered the effects of age and sex as possible
confounding variables. We calculated the summary esti-
mate of the prevalence odds ratio across strata of age and
sex using the Mantel-Haenszel method.
Sensitivity analysis
To quantify the possible effect of an unmeasured con-
founder on the observed prevalence odds ratios, we con-
ducted quantitative sensitivity analyses based on simple
methods [16]. This analysis estimated prevalence odds
ratios for migraine following adjustment for an unmeas-
ured dichotomous confounder that varied in prevalence
and varied in the degree of association with migraine. We
calculated adjusted odds ratios assuming that the preva-
lence of the confounder in the IBS cohort ranged from
10% to 90%, and that the odds ratio for the association
between the unmeasured confounder and migraine varied
from 2 to 10. We assumed that the prevalence of the
unmeasured confounder in the non-IBS comparison
cohort remained at 20%.
In another sensitivity analysis, we quantified the effect of
outcome misclassification on the prevalence odds ratios.
Although we developed operational definitions to iden-
tify the three disorders in medical claims data, there may
be clinical inconsistency in the diagnosis of these condi-
tions. These inconsistencies could include false-positive
or false-negative diagnoses by a clinician. Using fibromy-
algia as an example, we varied the hypothesized sensitivity
and specificity of the outcome to assess the effect of possi-
ble diagnosis error. In these calculations, we assumed that
the sensitivity and specificity of fibromyalgia detection
was non-differential between the IBS and non-IBS
cohorts. We calculated simulated prevalence odds ratios
accounting for the hypothesized levels of misclassifica-
tion.
Privacy and confidentiality
All analyses and reporting for this research were per-
formed using de-identified data with respect to Protected
Health Information. Under the Health Insurance Portabil-
ity and Accountability Act (HIPAA) of 1996, this research,
using encrypted automated data, did not require approval
by a Privacy Board or Institutional Review Board.BMC Gastroenterology 2006, 6:26 http://www.biomedcentral.com/1471-230X/6/26
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Results
Study population
We identified 97,593 people in the IBS cohort, and a ran-
dom sample of 27,402 people to compose the non-IBS
comparison cohort as a 5% random sample. The distribu-
tion of people in the two cohorts by age category and sex
is shown in Table 1. Women constituted nearly 75% of
the people in the IBS cohort, while about half of the peo-
ple in the non-IBS cohort were women. The distribution
of people in the two cohorts according to age category was
nearly identical.
Prevalence of migraine, fibromyalgia, and depression
The prevalence of migraine, fibromyalgia, and depression
in the IBS and the non-IBS comparison cohorts are shown
in Table 2. The table shows the prevalence of all three con-
ditions, the prevalence of people with two-way combina-
tions of conditions, and the prevalence of people with all
three conditions. Among the IBS cohort, the prevalence of
having at least one of the three disorders (migraine,
depression, or fibromyalgia) was 264 per 1,000 people. In
contrast, the prevalence of having at least one disorder
was 118 per 1,000 people in the non-IBS cohort, corre-
sponding to a pooled difference in the prevalence
between the two cohorts of 46 per 1,000 people (95% CI
42 – 51). In both cohorts, depression was the most preva-
lent condition, occurring in 128 per 1,000 people in the
IBS cohort, and 60 per 1,000 people in the comparison
cohort (pooled prevalence difference 16 per 1,000, 95%
CI 13 – 20).
Adjusted prevalence odds ratios
Crude and pooled prevalence odds ratios for the three dis-
orders are shown in Table 3. For all odds ratios, adjust-
ment for age, sex, and the mean cost of medical services
per person-month of health plan enrollment, substan-
tially lowered the crude point estimate. Overall, people in
the IBS cohort had a 60% higher odds of having one of the
three conditions relative to the comparison cohort
(pooled POR 1.6, 95% CI 1.5 – 1.7). For migraine, people
in the IBS cohort had a 60% higher odds compared with
people in the non-IBS cohort (pooled POR 1.6, 95% CI
1.4 – 1.7). The prevalence odds of fibromyalgia was 1.8-
times greater in the IBS cohort relative to the comparison
cohort (pooled POR 1.8, 95% CI 1.7 – 1.9). There was a
40% higher odds of depression in the IBS cohort relative
Table 1: Number of people in the IBS and non-IBS cohorts by age 
and sex, January 1996 through June 2002
IBS cohort Non-IBS cohort
No. of People Percent No. of People Percent
Female
18–29 13,791 19.6 3,291 23.2
30–39 16,435 23.3 3,409 24.1
40–49 19,263 27.3 3,811 26.9
50–64 18,837 26.7 3,430 24.2
65+ 2,149 3.0 229 1.6
Total 70,475 100 14,170 100
Male
18–29 5,224 19.3 2,434 18.4
30–39 6,972 25.7 3,094 23.4
40–49 6,993 25.8 3,759 28.4
50–64 6,925 25.5 3,638 27.5
65+ 1,004 3.7 307 2.3
Total 27,118 100 13,232 100
Total
18–29 19,015 19.5 5,725 20.9
30–39 23,407 24 6,503 23.7
40–49 26,256 26.9 7,570 27.6
50–64 25,762 26.4 7,068 25.8
65+ 3,153 3.2 536 2.0
Total 97,593 100 27,402 100
Table 2: Prevalence of migraine, fibromyalgia, and depression, IBS and non-IBS cohorts, January 1996 through June 2002
IBS cohort (n = 97,593) Non-IBS cohort (n = 27,402)
Cases Prevalence
per 1,000
Cases Prevalence
per 1,000
Pooled Prevalence
Difference*
(95% CI)
Migraine 5,890 60 611 22 5 (3 – 7)
Fibromyalgia 12,563 129 1,297 47 28 (25 – 31)
Depression 12,533 128 1,644 60 16 (13 – 20)
Any of the above 25,783 264 3,226 118 46 (42 – 51)
Depression and Fibromyalgia 2,149 22 146 5 2 (1.5 – 3)
Migraine and Fibromyalgia 1,032 11 66 2 1 (-0.2 – 2)
Depression and Migraine 924 10 74 3 0 (-0.2 – 0.3)
Depression, Migraine, and Fibromyalgia 549 6 20 1 0 (-0.5 – 1)
*Prevalence difference adjusted for categories of sex and quintile of mean medical costs per person-month of health plan enrollment.BMC Gastroenterology 2006, 6:26 http://www.biomedcentral.com/1471-230X/6/26
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to the comparison cohort (pooled POR 1.4, 95% CI 1.3 –
1.4).
Sensitivity analysis
Results of the sensitivity analysis of adjustment for an
unmeasured dichotomous confounder are depicted
graphically in Figure 1. The crude odds ratio for migraine
was 2.8, and the analysis showed that a null association
would have been observed after adjustment if there had
been both a substantial difference in the prevalence of the
confounder between the IBS and non-IBS cohorts and a
strong association between the confounder and migraine.
For example, an adjusted odds ratio of 1.0 for migraine
would have been observed if the prevalence of the con-
founder was 80% in the IBS cohort, and the odds ratio
between the confounder and migraine was 8.
Table 4 shows simulated crude prevalence odds ratios for
fibromyalgia according to the hypothesized levels of non-
differential sensitivity and specificity of outcome detec-
tion. The analysis indicated that imperfect sensitivity or
specificity of fibromyalgia detection would have biased
the observed prevalence odds ratio towards the null. The
rows correspond to the hypothesized levels of sensitivity,
and the columns correspond to the hypothesized levels of
specificity. The observed crude prevalence odds ratio was
3.0, which is shown in the cell with 100% sensitivity and
100% specificity. The observed prevalence odds ratio for
fibromyalgia would have been somewhat biased towards
the null if the sensitivity of detection was less than 100%.
For example, if the sensitivity of fibromyalgia detection
was 75% while the specificity remained 100%, the simu-
lated crude prevalence odds ratio would be 3.1. Bias
towards the null at a more substantial level would have
been introduced if the specificity of detection was less
than 100%. If the specificity of fibromyalgia detection was
98% while the sensitivity remained at 100%, the simu-
lated crude prevalence odds ratio would have been 4.4.
Discussion
Within a large, national health insurance plan, we identi-
fied a cohort of 97,593 people with IBS, and a comparison
cohort of 27,402 people that received routine medical
services. Among people with IBS, the odds of having at
least one of the three disorders was 60% greater compared
with people without IBS. As suggested in previous
Table 4: Simulated crude prevalence odds ratios for fibromyalgia according to hypothesized levels of observed non-differential 
sensitivity and specificity of outcome misclassification
Specificity
Sensitivity 100.0% 99.5% 99.0% 98.5% 98.0% 97.5% 97.0% 96.5% 96.0%
100.0% 3.0 3.2 3.5 3.8 4.3 5.1 6.2 8.3 13.2
95.0% 3.0 3.2 3.5 3.9 4.4 5.1 6.3 8.4 13.3
90.0% 3.0 3.2 3.5 3.9 4.4 5.1 6.3 8.4 13.4
85.0% 3.0 3.3 3.5 3.9 4.4 5.2 6.3 8.5 13.5
80.0% 3.0 3.3 3.6 3.9 4.5 5.2 6.4 8.5 13.6
75.0% 3.1 3.3 3.6 4.0 4.5 5.3 6.4 8.6 13.7
70.0% 3.1 3.3 3.6 4.0 4.5 5.3 6.5 8.7 13.8
Table 3: Prevalence odds ratios of migraine, fibromyalgia, and depression, January 1996 through June 2002
Crude Prevalence Pooled Prevalence
Odds Ratio (95% CI) Odds Ratio (95% CI)
Migraine 2.8 (2.6 – 3.1) 1.6 (1.4 – 1.7)
Fibromyalgia 3.0 (2.8 – 3.2) 1.8 (1.7 – 1.9)
Depression 2.3 (2.2 – 2.4) 1.4 (1.3 – 1.4)
Any of the above 2.7 (2.6 – 2.8) 1.6 (1.5 – 1.7)
Depression and Fibromyalgia 4.2 (3.6 – 5.0) 2.0 (1.7 – 2.3)
Migraine and Fibromyalgia 4.4 (3.5 – 5.7) 2.0 (1.5 – 2.5)
Depression and Migraine 3.5 (2.8 – 4.5) 1.5 (1.2 – 1.7)
Depression, Migraine, and Fibromyalgia 7.7 (5.0 – 12.1) 2.6 (1.7 – 4.1)
*Mantel-Haenszel prevalence odds ratio pooled across categories of sex and quintile of mean medical costs per person-month of health plan 
enrollment.BMC Gastroenterology 2006, 6:26 http://www.biomedcentral.com/1471-230X/6/26
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research, we observed these three disorders to have a
greater prevalence among people with IBS in comparison
to those without IBS.
The crude, unadjusted, comparisons of the IBS to the non-
IBS cohort provide an expectation of the prevalence of
diagnoses of migraine, depression, and fibromyalgia in a
group of people with IBS. This result can be useful for pre-
dicting use of health services, such as in an office setting.
The adjusted results provide information relating to a
causal effect of IBS, and addresses whether having IBS
increase the prevalence of these conditions. The preva-
lence odds ratios were pooled across strata of age, sex, and
quintile of the mean cost of medical services per person
per month. The mean cost of medical services reflects the
average consumption of health care services, and was
intended to serve as a proxy measure for disease severity.
Although disease severity itself is not a confounder, it cre-
ates a source of information bias that acts like a confound-
ing variable owing to differential disease surveillance.
Adjustment for these variables shifted the direction of the
prevalence odds ratios towards the null for all of the point
estimates. While the prevalence odds ratios were still ele-
vated in the direction of excess prevalence in the IBS
cohort, it is possible that using another variable that rep-
resented direct clinical measurements of disease severity
could have improved adjustment for confounding. Such a
shift from crude to pooled odds ratios suggests that
improved adjustment in confounding could have resulted
in a null association.
The sensitivity analyses illustrate some of the assumptions
that underlie this study. Although residual confounding
by an unmeasured variable can never be entirely ruled-out
in epidemiologic research, the sensitivity analysis of
adjustment for an unmeasured confounder indicated that
the observed odds ratio would have been biased only if
the prevalence of the confounding variable was extremely
disproportionate between the IBS and non-IBS cohorts,
and if there was a strong association between the con-
founder and migraine. This variable could be a common
physiologic pathway of IBS and migraine. The sensitivity
analysis for misclassification of fibromyalgia showed that
variation in the correspondence of the insurance claims to
Sensitivity analysis of adjustment for an unmeasured dichotomous confounder on the prevalence odds ratio for migraine* Figure 1
Sensitivity analysis of adjustment for an unmeasured dichotomous confounder on the prevalence odds ratio for migraine*. * 
Assumes a confounder prevalence of 20% in the non-IBS cohort.BMC Gastroenterology 2006, 6:26 http://www.biomedcentral.com/1471-230X/6/26
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actual clinical diagnoses could introduce bias. Sensitivity
of fibromyalgia detection would have a small effect on the
observed odds ratio. Variation in the specificity of fibro-
myalgia detection, on the other hand, would have greater
effect on the observed odds ratio, resulting in more sub-
stantial bias towards the null than variation in the sensi-
tivity. In interpreting the main findings of this study, we
assume there are no unmeasured confounding variables
and that the sensitivity and specificity of outcome detec-
tion is 100%. The sensitivity analyses, however, illustrate
how violations of these assumptions could lead to a
change in the interpretation of the results. The interpreta-
tion could change to one of no association between the
IBS and non-IBS cohorts, if the presence and association
with an unmeasured confounding variable was large
enough. Alternatively, the interpretation could change to
one of association of a considerable magnitude between
IBS and the three disorders, if the degree of outcome mis-
classification was high.
The data used for this study were medical and pharmacy
claims from a large, national health insurer. A limitation
of the insurance claims data is that socioeconomic and
quality of life measures, such as work absenteeism, which
would be of considerable importance to an analysis of
people with multiple comorbidities, are not obtainable.
Further, since the people included in this study were those
with commercial health insurance enrollment, the
observed prevalence may be different than among people
who may have different access to health services, such as
those without health insurance, or other forms of insur-
ance, such as government-sponsored Medicare or Medic-
aid plans.
All variables used in this study were derived from data ele-
ments ascertained from claims submitted for reimburse-
ment, such as ICD-9 diagnosis codes and CPT-4
procedure codes. People in the IBS cohort were identified
because they had a medical claim for health services asso-
ciated with an ICD-9 diagnosis code of irritable bowel
syndrome. The predictive value of an ICD-9 diagnosis
code corresponding to IBS has been shown be around
80% [17,18], representing an IBS prevalence of 1.6% in
this insured population [17]. However, there are limita-
tions to using an insurance claims-based approach to clas-
sifying people with the disorder. One limitation is that
were unable to ascertain clinical characteristics. This infor-
mation might be obtainable through other primary data,
such as through a physical examination or interview.
These clinical characteristics might confound the relation
we reported, or modify it. These data would also permit
further evaluation of disorders and symptoms which are
poorly reflected in insurance claims data, such as sleep
disorders, chronic fatigue syndrome, and PTSD. Primary
data would also permit confirmation of the diagnoses of
IBS, fibromyalgia, depression, and migraine. For example,
people with IBS are typically characterized according to
their predominant symptom of constipation or diarrhea.
In this analysis, however, we were unable to classify peo-
ple according to their predominant symptom in the IBS
cohort. We were therefore unable to assess whether there
was heterogeneity in the prevalence of these conditions in
the IBS cohort according the predominant symptom.
Conclusion
People in the IBS cohort had a 40% to 80% higher preva-
lence odds of migraine, fibromyalgia, and depression in
comparison to people without IBS.
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